MassDevice is liveblogging the MassMEDIC 11th Annual Medtech Investors Conference. We’re talking to the officers and executives of some of the hottest under-the-radar medical device firms around, finding out how and why their technologies will separate them from the pack.
Biorasis, Storrs, Conn.
Biorasis is developing a a wireless, miniaturized, implantable glucose sensor for long-term diabetes management.
Officers
Ioannis Tomazos, CEO
Fotios Papadimitrakopoulos, VP of Research
Faquir Jain, VP of Research
Product
Biorasis seeks to commercialize a wireless, miniaturized implantable glucose sensor for long-term diabetes management. The unique aspect of our patented sensor stems from technological innovations in sensor (i) powering, (ii) logic, (iii) wireless communication, (iv) auto-calibration, (v) biocompatible coatings, and (vi) miniaturized size (0.5×0.5×5 mm). The revolutionary size of our sensor is 00 times smaller than our closer competitor and permits implantation through a regular 16-gauge hypodermic needle. An implant of such small size substantially reduces tissue injury and at the same time increases patient acceptability.
Biorasis glucose sensing products target: (i) the human diabetes market, and (ii) the drug development market. These two markets possess different barriers of entry. The drug development market has a smaller barrier of entry, because it does not require FDA approval as the human market does. In addition, the unique size of our sensor provides the competitive advantage in the drug-development market, where 9 % of research animals are small rodents and therefore our competitors (due to their sensor size) are excluded. A market feasibility study performed by an independent third party indicated that the market acceptance rate for the drug development and human markets are 53% and 17%, respectively.
